“Shielding” Macrophages: Uncovering Immune-Mediated Chemoresistance in Triple-Negative Breast Cancer
Problem
Triple-negative breast cancer (TNBC) is one of the hardest types to treat and affects Māori and Pacific women more than others. Many patients with TNBC don’t fully respond to chemotherapy, and doctors can’t yet reliably predict who will or won’t benefit. A type of immune cell called a macrophage may be helping cancer survive treatment, but we don’t yet fully understand how.
Project
Researchers have found a group of macrophages that “shield” cancer cells from chemotherapy. In this project, they will:
-
identify what makes these shielding cells unique,
-
map where they sit in real patient tumours, and
-
switch off key genes in these cells to find out which ones help protect the cancer.
Outcome
The research will help discover new biomarkers so doctors can better predict how a patient with TNBC will respond to treatment and personalise their care.
Future
In the long term, this work could lead to new treatments that block “shielding” macrophages, making chemotherapy more effective and improving outcomes - especially for Māori and Pacific women.
Keep reading
View all
Using Deep Learning And Digital Pathology To Intrinsically Subtype Breast Cancer
Problem:Traditional pathology uses microscopes to examine tissue slides, but this method can be slow and inconsistent, and not all patients can afford advanced molecular testing. Project:Digital pa...
“Shielding” Macrophages: Uncovering Immune-Mediated Chemoresistance in Triple-Negative Breast Cancer
ProblemTriple-negative breast cancer (TNBC) is one of the hardest types to treat and affects Māori and Pacific women more than others. Many patients with TNBC don’t fully respond to chemotherapy, a...
Next-Generation Homocamptothecin Payloads for Antibody-Drug Conjugates
Problem: Some powerful cancer medicines called ADCs (antibody–drug conjugates) work really well, but one important type of ingredient they could use - homocamptothecins - is barely used because the...
